Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06397651
Other study ID # Pro00077693
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 12, 2024
Est. completion date February 28, 2026

Study information

Verified date May 2024
Source Complement Theory Inc.
Contact Anupam Anand, BTech
Phone +918473994735
Email anupam@compthealth.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A Decentralized, Double-blinded, Randomized, 18 month, Parallel-group, Superiority Study to evaluate the impact of Complement Theory's Live 1:1 Exercise Coaching and Personalized Digital Application on Cancer Survivors' Cost of Care


Description:

The randomized controlled trial (RCT) aims to evaluate the efficacy of Complement Theory's (CT) personalized and interactive, evidence-backed lifestyle program in reducing healthcare costs and improving health outcomes for survivors across all major cancer types. Distinct from conventional interventions, CT's program offers live 1:1 coaching through a mobile app, concentrating on Exercise and Meditation, and is enriched with evidence-based advice on Diet, Sleep, and comprehensive lifestyle modifications. This trial is pivotal in assessing the program's effectiveness against an active comparator- expert-recommended lifestyle modification resources suitable for cancer survivors--to isolate the impact of coaching and personalization. The primary objective is to investigate whether CT's novel approach can more effectively reduce healthcare utilization, through reduction of hospitalizations, urgent care visits, and outpatient visits. Furthermore, the trial seeks to measure adherence to treatment, and significant health outcomes, including improvements in Quality of Life Scores (QoLS) to provide a holistic evaluation of the program's impact on patient care and well-being. As an exploratory effort, the trial will also measure cancer progression, recurrence in Prostate and Colorectal cancer survivors alone.


Recruitment information / eligibility

Status Recruiting
Enrollment 146
Est. completion date February 28, 2026
Est. primary completion date February 28, 2026
Accepts healthy volunteers No
Gender All
Age group 21 Years to 64 Years
Eligibility Inclusion Criteria: - Cancer Type: Breast, Prostate, Colorectal, Lung and Other Cancer - Cancer Stage: Stage 1 to 4 - Treatment Status: Has undergone any cancer-related treatment in last 12 months - Age: 21 to 64 - Permission to access to last 1 year digital health records - Access to smartphone or a tablet Exclusion Criteria: - Excludes individuals who have undergone surgery within the last 4 weeks or will undergo surgery in the next 4 weeks - Participants declared medically unfit by their physicians to do physical exercise - ECOG Score 3,4 or 5

Study Design


Intervention

Behavioral:
Complement Theory's Live 1:1 Exercise Coaching and Personalized Digital Application
Participants will get access to Complement Theory's 24-week Live 1:1 Coaching program, focusing on Exercise and Meditation and supplemented with evidence-based information on Diet, Sleep, and other lifestyle practices, adjunct to the core treatment. Each week, up to five sessions of 45 minutes each will be offered, with a recommendation for participants to engage in a minimum of three sessions to ensure adequate program exposure and benefits. Each session will consist of 30 Minutes of Physical Exercise and 7 minutes of meditation. Each session will be a combination session focused on Aerobic and Strength, with flexibility and balance exercises included as supplements.
Digital application with expert guidelines on lifestyle modification
24 weeks access to Digital application with expert guidelines on lifestyle modification focusing on exercise, meditation, as well as information on diet, sleep and other lifestyle practices.

Locations

Country Name City State
United States Complement Theory Inc. Dover Delaware

Sponsors (1)

Lead Sponsor Collaborator
Complement Theory Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total Healthcare Expenditure Reduction To quantify the impact of Complement Theory's Program on total healthcare expenditure in cancer survivors. This includes assessing both cancer-related and non-cancer-related costs, further categorized into planned and unplanned expenditures. 18 months
Secondary Adherence to Treatment Evaluate the effects of CT's Digital Application Program on adherence to treatment (using MMAS-8 survey) 18 Months
Secondary Influence on Quality of Life Score (QoLS), Pain, Sleep and Physical Activity Measure the program's influence on Quality of Life, Physical Activity, Sleep Quality and Pain levels of participants. 18 Months
Secondary Effect on Employee Absenteeism Quantify the effect of CT's program on employee absenteeism by tracking changes in the number of sick days taken by participants. 18 Months
Secondary Impact on Employee Presenteeism Determine the program's impact on employee presenteeism by assessing changes in work motivation and employee performance review scores. 18 Months
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2